Abstract
Introduction
The clinical effectiveness of a new medical test is determined by the extent to which incorporating the test into clinical practice ultimately improves patient health outcomes. This depends on a series of factors. For example, the clinical effectiveness of positron emission tomography (PET) in the assessment of patients with head and neck cancer for radiotherapy depends on its accuracy to delineate the tumour, changes in the radiotherapy regimen following PET, and consequences of these changes on patient survival and quality of life (19) .
Randomized controlled trials (RCTs) of tests that capture the entire clinical pathway between testing and health outcomes provide direct evidence of the clinical effectiveness of a test.
Although ideal, these studies are not often done and are sometimes not feasible (4) . For fast evolving technologies like medical tests, reviewers will rarely find direct trial evidence and therefore must often rely on evidence about test accuracy and other factors to draw conclusions about clinical effectiveness.
Within the test evaluation framework of Fryback and Thornbury (7), these factors can be regarded as critical steps along the clinical pathway linking the use of the test to patient health outcomes ( Figure 1 ). Diagnostic accuracy is a measure of how well a test identifies patients with and without a disorder, commonly reported as test sensitivity and specificity (5) . For the purpose of this report, we have defined the direct consequences of test results, such as changes in therapeutic decisions, that can have downstream consequences for health outcomes, as 'intermediate' test outcomes. Health outcomes refer to measurement of the health state of patients, which are ideally measured in treatment RCTs (17) .
All these outcomes are relevant in the assessment of medical tests. Information from studies investigating test accuracy can sometimes be directly linked with health outcomes from RCTs showing that treatment for the target condition is effective to draw conclusions about the health benefits of detecting disease (15) . This requires that the spectrum of disease defined by the new test is representative of cases included in the treatment RCTs. peripheral to our study, such as patient or clinician confidence and testing or screening compliance, were not examined further. To be eligible for our review, HTAs had to be reports of human studies with a full report in English. We excluded methodological reviews, horizon scanning studies, newsletters, pure economic studies, reviews comparing different generations of the same technology, and guidelines for tests already used in clinical practice.
Methods

Identification of HTA reports
Assessment of HTA reports
We extracted general information about the name of the test, the proposed role of the test, the disease and patient group to be tested, and outcomes mentioned for each eligible HTA.
Reports were classified according to the type of investigated test: screening (asymptomatic populations) (9); diagnosis (detecting or excluding disorders in symptomatic populations) 
Results
Characteristics of identified HTA reports
We identified 318 non-duplicate records. Ninety-seven of these were excluded because the main focus was not test evaluation; 38 did not present data on accuracy, intermediate outcomes or patient health outcomes; 22 were horizon scanning reports or economic evaluations; and 12 were guidelines for tests already in use.
The included 149 HTAs were prepared by 18 agencies in eight countries. The types of tests evaluated were for screening (24%), diagnosis (25%), disease classification of established diagnosis (32%), or multiple purposes (19%). The most common disease areas were oncology (38%) and the circulatory system (17%), followed by endocrine and metabolic diseases (6%), infectious diseases (5%), and multiple disease areas (6%) ( Table 1) . Additional information and weblinks to all included HTAs are available in Supplementary Table 1 .
Accuracy
Seventy-one of the 149 included HTAs (48%) reported solely on diagnostic accuracy. In 42 (59%) of these assessments we found a clear conclusion about the clinical effectiveness of the test. These conclusions were negative (that is, the test was not effective) in 19 assessments and positive (the test was effective) in 16, while in the remaining 7 assessments the authors argued that there was not enough evidence to support definitive conclusions about the effectiveness of the test to improve health outcomes.
Patient health outcomes
In addition to accuracy, evidence of patient health outcomes was reported in 17 HTAs (11%).
Common outcomes were treatment success, disease progression, and treatment complication rates. Thirteen of the 17 HTAs (76%) had clear conclusions about the clinical effectiveness of the test. These conclusions were positive in 6 HTAs and negative in one. In 6 HTAs it was concluded that evidence for final conclusions about the clinical effectiveness of the test was lacking. (7) is arguably the most prominent of these frameworks, and similar schemes have been proposed (14) . They share the basic principle of a hierarchy of types of outcome, starting with technical efficacy at the lowest level and then progressing sequentially to diagnostic accuracy, diagnostic thinking, therapeutic impact, patient health outcomes, and societal aspects. In this hierarchy, therapeutic impact provides higher level evidence of test effectiveness than accuracy. When a test has been shown to be accurate and its purpose is to improve treatment selection, change in patient management is a necessary condition for the test to improve health outcomes. It is, however, not a sufficient condition, because the test result is often only one of several factors influencing patient management, and a change of management does not necessarily lead to improved outcomes. Hence, intermediate outcomes may help answer some questions about the consequences of testing but leave reviewers with open issues about how to judge whether this evidence is an adequate surrogate for patient health outcomes.
Intermediate outcomes
To make valid judgments when evaluating change in patient management, we propose a structured approach that starts with making a claim about what change in patient management will occur as a consequence of the test results and how this is expected to lead to improved health outcomes. The type of management change specified and assumptions required to infer impact on health outcomes will then inform the formulation of research questions for the test HTA (Box 1). This approach is similar to the methodology of realist synthesis developed for complex policy interventions (21) . Indeed, change in patient management may provide important evidence for realist reviews of tests. When the consequences of test results are not well established, evidence about patient management will be relevant for assessment. In these situations, the second step for reviewers is to specify what management changes are anticipated and the assumptions required to link the management changes to change in health outcomes (Box 1). These assumptions are critical to interpretation of the evidence and ideally should be tested. We found that the key assumptions were identified in most HTAs we reviewed but not all. Evidence from published studies was often used to support these assumptions. Expert opinion is required to infer whether evidence of effective treatment from these studies can be applied to the new setting which includes the test in review. In the assessment of PET for head and neck cancer, a panel of oncologists and radio-oncologists judged that increased radiotherapy due to PET-detected additional lymph node metastases is likely to improve health outcomes based on existing evidence of the effectiveness of radiotherapy on cervical lymph node metastases (19) . Such a judgment needs to weigh up the likelihood and extent of the benefits of changed management against its potential harms. However, in many of the reviewed assessments the statements of assumptions could not easily be located; they were often somewhat hidden in the discussion.
We suggest giving this important issue a more prominent place in a dedicated paragraph of test HTAs.
If assumptions that changes in patient management are likely to improve outcomes appear to be reasonable, the third step is a review of the evidence for changed management (Box 1).
Included studies need to report their results with a minimum standard of detail in order to be interpretable. Simply reporting a rate of 'overall change' is not informative. Information about the direction and extent of changed treatment after a positive and negative test result is needed to estimate the impact on health outcomes. The assumptions used for these conclusions should be explicitly stated as discussed above. Disappointingly, in only about a third of reviewed HTAs were the included primary studies sufficiently reported to allow an interpretation of changed patient management stratified by test result. Interpretation also requires information about test accuracy to determine what proportion of patients receives a change in management based on a correct diagnosis and what proportion has management changed due to a false positive or false negative test result.
In the fourth step, the quality appraisal of this evidence, reviewers have to judge whether the included studies are able to demonstrate a true change in patient management (Box 1). The different study designs are prone to varying types of bias (25) . If these studies do not measure actual management in patients randomly allocated to different test strategies, the outcome is often a hypothetical assessment of planned management in a patient cohort, so it remains unclear to what extent the measured changes in planned management reflect actual clinical practice. These limitations always need consideration. We also found inconsistent use of different appraisal tools. For a systematic review evaluating the added value of structural neuro-imaging with computed tomography or magnetic resonance imaging compared with current practice in the assessment of psychotic patients (2), the authors adapted an appraisal tool commonly used for accuracy studies (QUADAS) to assess the included diagnostic before-after studies. Their subsequent publication of this method (16) is an important step towards a more consistent appraisal of these studies. However, the sources of bias relevant to accuracy studies, particularly in the verification of test results with the reference standard, do not apply to assessing the impact of test information on downstream health outcomes. More important are the types of bias encountered in intervention studies, such as differences in patient characteristics between tested groups, differences in the measurement of outcomes, or differences in the reporting of outcomes (11) . In addition, appraisal should include assessing the validity of the study authors' assumptions for inferring that management is a good proxy for outcomes. This review has some limitations. Because of financial and time restraints we included only English-language assessments. We believe that our sample is representative of HTAs in the current published English literature, but the extent to which the results can be applied to other HTA settings is debatable. However, the primary aim of this review was to document the range of approaches to test evaluation used by different agencies. We believe that the HTAs used here are appropriate to document this issue. Some of the information extracted for this review was subjective, such as whether conclusions about the effectiveness of tests on improving health outcomes were clearly stated. Although two investigators (SD, LS) independently rated the included assessments and agreed on a consensus rating in cases of initial disagreement, these judgements cannot be fully objective. Finally, in undertaking this review, we have presented a framework for test evaluation that has been used by the Australian MSAC. We are aware that different agencies may hold slightly different views; we anticipate this review will stimulate discussion about the use of intermediate outcomes in medical test assessments. In particular, we have identified the need for further research in the HTAi community to establish criteria for assessing the quality of primary studies and judging the validity of assumptions when using patient management as a surrogate for health outcomes. We hope that the recommendations in our Box can be a departure point for these discussions.
In conclusion, we have demonstrated that intermediate outcomes are frequently used in medical test HTAs, but interpretation of this evidence is inconsistently reported. We recommend that reviewers routinely explain the rationale for using intermediate outcomes to 
Box 1
Incorporating evidence of test impact on patient management in HTAs of medical tests 
